Drugs Gene Sequencing Genetics 
pharmaphorum
MARCH 10, 2022
18 months after signing its first partnering deal with Genentech, Scenic Biotech has raised $31 million in first-round financing that it will use to take its own genetic modifier-targeted medicines into clinical trials. Scenic has developed a series of small-molecule drugs targeting QPTCL that block the expression of CD47 on cancer cells.
pharmaphorum
APRIL 23, 2021
billion in milestone payments in the deal, which will focus on using small-molecule compounds to “fine tune” the effects of genetic medicines in the body. The approach relies on the use of drug responsive domains (DRDs) on the gene-editing medicine, which can be used to either increase or decrease protein expression.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
pharmaphorum
AUGUST 10, 2021
Europe market has proved so hostile to gene therapies when it comes to pricing and reimbursement for gene therapies that bluebird bio has decided to quit the market altogether, according to Andrew Obenshain, president of its severe genetic diseases unit. market and will wind down in Europe.
pharmaphorum
AUGUST 10, 2021
Oxford University and UK clinical artificial intelligence (AI) company Sensyne Health will partner on a project to find new drug targets for people with hard-to-treat asthma. Dr Timothy Hinks. According to Hinks, “we still don’t understand the causes of asthma, because in the past the scientific tools just didn’t exist.
pharmaphorum
JUNE 23, 2022
The deal comes a year after Intellia and partner Regeneron reported promising results from the first clinical trial of a drug used to edit the genomes of cells within the body, in patients with rare disease ATTR amyloidosis. billion in potential milestones if the project advances through development and onto the market.
Roots Analysis
FEBRUARY 23, 2022
You may also be interested in the following titles: P eptide Therapeutics: Contract API Manufacturing Market Immune Checkpoint Inhibitors (PD-1 & PD-L1 Targeting Drugs) Artificial Intelligence in Healthcare. Our Social Media Platform. Web: [link]. LinkedIn: [link]. Twitter: [link].
The Pharma Data
DECEMBER 28, 2020
About Fulgent Genetics. Fulgent Genetics’ proprietary technology platform has created a broad, flexible test menu and the ability to continually expand and improve its proprietary genetic reference library while maintaining accessible pricing, high accuracy and competitive turnaround times. TEMPLE CITY, Calif.,
Expert insights. Personalized for you.
98 
Let's personalize your content